NCT05753592View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

December 14, 2023

Study Completion Date

December 17, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

Part 1; LOU064 (Remibrutinib)

25 mg remibrutinib (5.5 days)

DRUG

Part 2; LOU064 (Remibrutinib)

25 mg remibrutinib (5.5 days)

Trial Locations (1)

H-3529

Novartis Investigative Site, Miskolc

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY